Compare ELF & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELF | PBLS |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 2016 | 2026 |
| Metric | ELF | PBLS |
|---|---|---|
| Price | $63.18 | $27.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 17 | 0 |
| Target Price | ★ $111.88 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | N/A |
| Earning Date | 05-27-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,636,472,000.00 | N/A |
| Revenue This Year | $23.87 | N/A |
| Revenue Next Year | $17.15 | N/A |
| P/E Ratio | $145.91 | ★ N/A |
| Revenue Growth | ★ 24.59 | N/A |
| 52 Week Low | $48.82 | N/A |
| 52 Week High | $150.99 | N/A |
| Indicator | ELF | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | N/A |
| Support Level | $58.05 | N/A |
| Resistance Level | $71.23 | N/A |
| Average True Range (ATR) | 3.77 | 0.00 |
| MACD | 1.35 | 0.00 |
| Stochastic Oscillator | 65.36 | 0.00 |
e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.